Detail akcie Milestone Pharma Rg online

Business Summary: Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Milestone Pharmaceuticals Inc revenues was not reported. Net loss increased 57% to $45.6M. Higher net loss reflects Commercial activities increase from $6.1M to $19.5M (expense), Research and development increase of 24% to $11.4M (expense), Interest income decrease of 36% to $2.1M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.49 to -$0.71.